Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
A Randomized Controlled Clinical Trial to Investigate the Effect of Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
Sponsor: The First Affiliated Hospital with Nanjing Medical University
A PHASE2/PHASE3 clinical study on Colon Cancer, this trial is ongoing. The trial is conducted by The First Affiliated Hospital with Nanjing Medical University and has accumulated 6 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.